Singapore
The startup's core offerings revolve around four key pillars. Firstly, the emphasis on product access highlights its role in providing a wide range of approved, validated, and affordable COVID-19 test products. This is further underscored by its compliance with ISO 13485:2016 standards and the presence of an on-the-ground team ensuring quality control.
Furthermore, ARISTA Biotech prides itself on an experienced team with a strong background in the pharmaceutical industry. This team's expertise spans high-throughput manufacturing, registration, product branding, and clinical trial management, underscoring their capability to navigate the complexities of the healthcare landscape.
The startup's global network is a strategic asset, with collaborative ties to laboratories, manufacturers, and R&D centers in the United States, United Kingdom, and Asia. Additionally, its expanding global sales network augments its reach and market presence, reflecting its ambition to make a significant impact at a global scale.
Lastly, ARISTA Biotech leverages IT platforms to integrate data, manage population testing, store test records, and generate digital test certificates. This technological integration underscores the company's commitment to leveraging innovative solutions to streamline processes and enhance effectiveness.
Operating within the healthcare and pharmaceutical industries, ARISTA Biotech was founded in 2020. Although information regarding the last investment and associated investors is currently unavailable, the startup's strategic positioning, industry relevance, and response to the pressing challenges of COVID-19 make it a compelling candidate for potential investment consideration.
